Nevanac 1mg/ml eye drops suspension - (emc) | 6549
Nevanac 1mg/ml eye drops suspension - Summary of Product Characteristics (SmPC) by Novartis Pharmaceuticals UK Ltd
www.medicines.org.ukHere’s the latest general context on Nevanac (nepafenac) eye drops from reliable sources:
Nevanac is an NSAID eye drop used to reduce pain and inflammation after cataract surgery, and to lower the risk of macular edema in diabetic patients after cataract surgery in adults. It is available by prescription and is typically administered as one drop in the affected eye(s) several times daily depending on the strength and indication. This aligns with EMA labeling and regulatory summaries [EMA EPAR; SmPC summaries].[2][3]
Common safety notes include potential corneal irritation or epithelial changes; severe cases of corneal damage require discontinuation and medical monitoring. Post-marketing experience has reported corneal epithelium defect/disorder, with severity ranging from minor to requiring intervention [EMA EPAR; SmPC].[4][2]
Treatment duration varies by indication: up to 60 days in some postoperative macular edema prevention protocols, and shorter courses for routine postoperative inflammation control. These durations are described in regulatory documents and national assessments [NHS Scotland appraisal; EMA SmPC].[1][3][2]
Important practical notes for patients: avoid wearing contact lenses during treatment (or follow clinician guidance), and monitor for signs of eye irritation, worsening redness, or vision changes. Allergic reactions or hypersensitivity to nepafenac or other NSAIDs should prompt medical consultation. These cautions appear in product information and regulatory summaries [EMA EPAR; SmPC].[3][4]
If you’d like, I can:
Would you like me to focus on a particular country or format (bullet summary, patient handout, or quick dosing chart)? I can also fetch the exact smPC excerpts if you want precise language. I’ll include up-to-date citations with each point.
Nevanac 1mg/ml eye drops suspension - Summary of Product Characteristics (SmPC) by Novartis Pharmaceuticals UK Ltd
www.medicines.org.ukNHS Scotland. The advice is summarised as follows: ADVICE: following a full submission nepafenac (Nevanac®) is accepted for use within NHS Scotland. Indication under review: reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients. In the pivotal study which included diabetic patients who had undergone cataract surgery, nepafenac eye drops significantly reduced the incidence of macular oedema compared to vehicle. Overleaf is the detailed...
scottishmedicines.org.uk## Nevanac is an eye drop suspension that contains the active substance nepafenac (1 and 3 mg/ml). ## Nevanac is used in adults to prevent and treat the pain and inflammation that can occur after an operation to remove a cataract from the eye. Nevanac is also used to reduce the risk of macular oedema (swelling in the macula, the central part of the retina at the back of the eye) that can occur after cataract surgery in adult diabetes patients. The medicine can only be obtained with a...
www.ema.europa.euimmediately discontinue use of NEVANAC and should be monitored closely for corneal health (see section 4.4). From post-marketing experience with NEVANAC 1 mg/ml eye drops, suspension, cases reporting corneal epithelium defect/disorder have been identified. Severity of these cases vary from non serious
www.ema.europa.euFind patient medical information for Nevanac (nepafenac) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
www.webmd.com